{
    "nct_id": "NCT04097028",
    "official_title": "Use of Trifluridine/Tipiracil (TAS-102) and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction (GEJ) Adenocarcinoma",
    "inclusion_criteria": "* Must have histologically proven loco-regional esophageal or gastroesophageal junction adenocarcinoma\n* Endoscopic ultrasound (EUS), or clinically determined node-positive disease with any T-stage or T3-T4a with any N stage: Patients with EUS T4b and any M1 cancer will not be included\n* Must have potentially resectable disease\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Hemoglobin >= 9 g/dL\n* Absolute neutrophil count >= 1500/mm^3\n* Platelet count >= 100,000/mm^3\n* Creatinine < 1.5 upper limit of normal (ULN)\n* Bilirubin < 1.5 x ULN\n* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN\n* Capacity to take oral tablet(s) without difficulty\n* Participants of child-bearing potential must agree to use highly effective contraceptive methods (e.g., hormonal plus barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior chemotherapy, thoracic radiotherapy or prior surgical resection for an esophageal tumor\n* Participants with known metastatic disease\n* Any concurrent active malignancy that requires active systemic intervention\n* Grade 2 or higher peripheral neuropathy\n* Participants who have had major surgery or field radiation within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier\n* Received an investigational agent within 4 weeks prior to enrollment\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Grade 3 or higher hypersensitivity reaction to oxaliplatin or grade 1-2 hypersensitivity reaction to oxaliplatin not controlled with premedication\n* Patient previously treated by TAS 102 or history of allergic reactions attributed to compounds of similar composition to TAS 102 or any of its excipients\n* Hereditary problems of galactose intolerance; e.g., Lapp lactase deficiency or glucose galactose malabsorption\n* Pregnant or nursing female participants\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug",
    "miscellaneous_criteria": ""
}